Tatjana Belovari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tatjana Belovari has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Nikola Bijelić
Department of Histology and Embryology, Faculty of Medicine Osijek, University of Osijek, J. Huttlera 4, 31000 Osijek, Croatia
3 shared publications - Edi Rođak
Department of Histology and Embryology, Faculty of Medicine Osijek, University of Osijek, J. Huttlera 4, 31000 Osijek, Croatia
2 shared publications - Jasmina Rajc
Faculty of Medicine, University J. J. Strossmayer Osijek, Osijek, Croatia
2 shared publications - Biljana Pauzar
Department of Histology and Embryology, Faculty of Medicine, Josip Juraj Strossmayer University, Osijek, Croatia; Department of Clinical Cytology, University Hospital Centre Osijek, Croatia
1 shared publication - Boris Dumenčić1 shared publication
- Domagoj Vučić
General Hospital “Dr. Josip Benčević“, Slavonski Brod, Croatia
1 shared publication
Latest Publications
- 1 November 2022
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 17 (9-10) , 266
Morphometric analysis of adipocytes in epicardial adipose tissue of the right atrium – preliminary data
- 1 November 2022
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 17 (9-10) , 266
Morphometric analysis of adipocytes in epicardial adipose tissue of the right atrium – preliminary data
- Open Access
- 12 November 2020
- Published by Faculty of Medicine Osijek in Southeastern European medical journal
- Vol. 4 (2) , 20-27
Neoadjuvant Chemotherapy Affects TFF3 Peptide Expression in Luminal B Subtype of Breast Cancer – A Pilot Study
Aim: Trefoil factor family 3 (TFF3) peptide is normally expressed by epithelial cells in breast ducts, but it is also associated with different pathological conditions, including breast cancer. It is considered a marker of poor prognosis and associated with increased resistance to chemotherapy. Data on the effect of chemotherapy on TFF3 peptide expression are scarce. The aim of this pilot study was to assess suitability of research on this topic for large-scale studies. Methods: Formalin-fixed, paraffin-embedded samples of core biopsies and of surgically removed tumors from patients with luminal B subtype of breast cancer were used for immunohistochemical analysis. Changes in TFF3 peptide and Ki-67 expression and microvessel density (MVD) values before and after chemotherapy were analyzed, as well as the association between TFF3 peptide expression and Ki-67 expression and MVD values. Results: Significant reduction in TFF3 and Ki 67 expression was observed after chemotherapy, while MVD values did not differ significantly before and after chemotherapy. The association of TFF3 peptide expression and Ki-67 expression and TFF3 peptide expression and MVD values was not significant before or after chemotherapy. Conclusion: The data obtained in this pilot study suggest that a large-scale study is justified, and it other breast cancer subtypes should be included.
- 12 November 2020
- Published by Faculty of Medicine Osijek in Southeastern European medical journal
- Vol. 4 (2) , 20-27
Open AccessNeoadjuvant Chemotherapy Affects TFF3 Peptide Expression in Luminal B Subtype of Breast Cancer – A Pilot Study
Aim: Trefoil factor family 3 (TFF3) peptide is normally expressed by epithelial cells in breast ducts, but it is also associated with different pathological conditions, including breast cancer. It is considered a marker of poor prognosis and associated with increased resistance to chemotherapy. Data on the effect of chemotherapy on TFF3 peptide expression are scarce. The aim of this pilot study was to assess suitability of research on this topic for large-scale studies. Methods: Formalin-fixed, paraffin-embedded samples of core biopsies and of surgically removed tumors from patients with luminal B subtype of breast cancer were used for immunohistochemical analysis. Changes in TFF3 peptide and Ki-67 expression and microvessel density (MVD) values before and after chemotherapy were analyzed, as well as the association between TFF3 peptide expression and Ki-67 expression and MVD values. Results: Significant reduction in TFF3 and Ki 67 expression was observed after chemotherapy, while MVD values did not differ significantly before and after chemotherapy. The association of TFF3 peptide expression and Ki-67 expression and TFF3 peptide expression and MVD values was not significant before or after chemotherapy. Conclusion: The data obtained in this pilot study suggest that a large-scale study is justified, and it other breast cancer subtypes should be included.
- 1 April 2013
- Published by Elsevier in Acta Histochemica
- Vol. 115 (3) , 204-208
Trefoil factor family protein 3 (TFF3) is present in cartilage during endochondral ossification in the developing mouse fetus
- 1 April 2013
- Published by Elsevier in Acta Histochemica
- Vol. 115 (3) , 204-208
Trefoil factor family protein 3 (TFF3) is present in cartilage during endochondral ossification in the developing mouse fetus